Study wrapper · #975
Cagrilintide lowers bodyweight through brain amylin receptors 1 and 3.
Carvas AO, Leuthardt A, Kulka P, et al. EBioMedicine. 2025.
DOI: 10.1016/j.ebiom.2025.105836PubMed: 40609154
Editor's note
A knockout-mouse study showing cagrilintide's body-weight effect requires amylin receptors 1 and 3, mapping its central mechanism to specific brainstem circuits. Findings are in mice and mechanistic, not clinical. Directly focused on a tracked peptide.
Plain-language abstract
In mice, cagrilintide's weight-lowering effect depended on brain amylin receptors 1 and 3.
Related coverage
Mixed
Amylin and the renin-angiotensin system: risk or opportunity in amylin-based therapy?
Lancet (London, England)n=——2026
Supported
Cagrilintide-semaglutide (CagriSema) versus semaglutide or cagrilintide in people with type 2 diabetes (REIMAGINE 2): a double-blind, randomised, controlled, phase 3 study.
The lancet. Diabetes & endocrinologyn=——2026
Supported
Cagrilintide-semaglutide (CagriSema) as an add-on to basal insulin in adults with type 2 diabetes (REIMAGINE 3): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study.
Lancet (London, England)n=——2026